A pharmacogenomic assessment of psychiatric adverse drug reactions to levetiracetam.
Ciarán CampbellMark McCormackSonn PatelCaragh StapletonDheeraj BobbiliRoland KrauseChantal DepondtGraeme J SillsBobby P KoelemanPasquale StrianoFederico ZaraJosemir W SanderHolger LercheWolfram S KunzKari StefanssonHreinn StefanssonColin P DohertyErin L HeinzenIngrid Eileen SchefferDavid B GoldsteinTerence O'BrienDavid CotterSamuel Frank Berkovicnull nullSanjay M SisodiyaNorman DelantyGianpiero L CavalleriPublished in: Epilepsia (2022)
The polygenic burden for schizophrenia is a risk factor for LEV-associated psychotic reaction. To assess the clinical utility of PRS as a predictor, it should be tested in an independent and ideally prospective cohort. Larger sample sizes are required for the identification of significant univariate common genetic signals or rare genetic signals associated with psychiatric LEV ADRs.